Edwards Lifesciences (EW) 18th Annual Emerging Technology Summit summary
Event summary combining transcript, slides, and related documents.
18th Annual Emerging Technology Summit summary
3 Feb, 2026Strategic priorities and business transformation
Focus on evolving from a meetings-centric brand to a comprehensive platform (Workplace) integrating chat, phone, email, calendar, and docs for seamless work experiences.
Expansion into adjacent growth areas, notably Contact Center and employee experience (Workvivo), to diversify revenue streams.
AI is a core priority, with efforts to embed and monetize advanced AI features across the platform, moving beyond meetings to broader workflows.
Stabilization of both online (40% of revenue) and enterprise (60%) segments post-pandemic, with renewed focus on growth, pricing, and customer needs.
Channel development and international expansion are key to driving enterprise growth, especially in meetings and phone.
AI strategy and monetization
Base-level AI features are included in paid SKUs at no extra cost to drive adoption and stickiness, differing from competitors' high per-user charges.
Monetization focuses on high-value scenarios: Contact Center, Custom AI Companion ($12/user/month), and vertical solutions for Healthcare, Education, and Frontline workers.
AI monetization models are primarily per user per month, with some movement toward consumption-based pricing for certain features.
Workplace pricing ranges from $15–$30 per user per month, with additional AI features layered on top.
Cost control in AI is achieved through a federated approach, leveraging both proprietary and open-source models to optimize quality and price.
Financial outlook and capital allocation
Operating margin guidance was updated to reflect a shift from stock-based to cash-based compensation, resulting in a one-point margin degradation by 2026.
Investments in operating income will be closely tied to demonstrated top-line growth, with a disciplined approach to spending.
M&A will target strategic synergies in core priorities, with a focus on small to medium-sized deals to accelerate execution.
The company maintains a strong cash position, enabling flexibility for both organic growth and acquisitions.
Pricing power and innovation are seen as levers for future growth, especially in the online segment targeting small businesses and solopreneurs.
Latest events from Edwards Lifesciences
- Strong clinical data and innovation drive growth outlook, with margin expansion and new therapies ahead.EW
Leerink Global Healthcare Conference 202611 Mar 2026 - Double-digit growth driven by TAVR, TMTT, and heart failure innovations, with margin expansion ahead.EW
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - TAVR and TMDT growth driven by innovation, clinical data, and expanding patient access.EW
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - TAVR acceleration, innovation, and regulatory changes drive confident growth outlook for 2026.EW
Citi’s 2026 Unplugged MedTech and Life Sciences Access Day26 Feb 2026 - Double-digit sales growth and raised 2026 guidance, led by TAVR and TMTT strength.EW
Q4 202511 Feb 2026 - 2026 targets 8%-10% sales growth and major innovation milestones in heart therapies.EW
Investor Day 20253 Feb 2026 - Q2 sales up 8%, TMTT surged, TAVR slowed, Critical Care sale and acquisitions reshape outlook.EW
Q2 20243 Feb 2026 - Critical care sale sharpens focus on structural heart, with TAVR and TMTT fueling growth.EW
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - TAVR and TMTT innovation, clinical trial expansion, and strong product adoption drive robust growth.EW
The 44th Annual William Blair Growth Stock Conference31 Jan 2026